ReviewCurrent gene therapy2009
Immunotherapy of human cancers using gene modified T lymphocytes.
Review in Current gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Trial
- Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma.Journal of hematology · 2023Review
- Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies.Bioengineering (Basel, Switzerland) · 2022Review
- Cancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications.Cancers · 2021Review
- Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.Journal of experimental & clinical cancer research : CR · 2019Review
- Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism.Frontiers in immunology · 2018Review
- Novel immunotherapies for hematologic malignancies.Immunological reviews · 2015Review
- Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.Prostate cancer and prostatic diseases · 2013Article
- Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Engineered T cells for pancreatic cancer treatment.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2011Article
- Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.Cancer immunology, immunotherapy : CII · 2011Review
- Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Review
- Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cells.PloS one · 2011Article
- Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Blood · 2010Review
- Immunotherapy prospects for acute myeloid leukaemia.Clinical and experimental immunology · 2010Review
- Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Adoptive T cell therapies can produce objective clinical responses in patients with hematologic and solid malignancies. Genetic manipulation of T lymphocytes has been proposed as a means of increasing the potency and range of this anti-tumor activity. We now review how coupling expression of transgenic receptors with countermeasures against potent tumor immune evasion strategies is proving highly effective in pre-clinical models and describe how these approaches are being evaluated in human subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.